CareDx Inc
$ 17.57
-0.34%
15 Apr - close price
- Market Cap 906,757,000 USD
- Current Price $ 17.57
- High / Low $ 18.23 / 17.02
- Stock P/E N/A
- Book Value 5.95
- EPS -0.40
- Next Earning Report 2026-04-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -0.06 %
- 52 Week High 21.48
- 52 Week Low 10.96
About
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
Analyst Target Price
$24.80
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-04 | 2025-11-04 | 2025-08-06 | 2025-05-07 | 2025-02-26 | 2024-11-04 | 2024-07-31 | 2024-05-09 | 2024-02-28 | 2023-11-08 | 2023-08-08 | 2023-05-10 |
| Reported EPS | 0.12 | 0.28 | 0.1 | 0.1 | 0.18 | 0.14 | 0.25 | -0.03 | -0.17 | -0.18 | -0.18 | -0.11 |
| Estimated EPS | -0.01 | -0.08 | -0.1 | 0.0683 | 0.1475 | 0.01 | -0.14 | -0.21 | -0.27 | -0.4 | -0.31 | -0.11 |
| Surprise | 0.13 | 0.36 | 0.2 | 0.0317 | 0.0325 | 0.13 | 0.39 | 0.18 | 0.1 | 0.22 | 0.13 | 0 |
| Surprise Percentage | 1300% | 450% | 200% | 46.4129% | 22.0339% | 1300% | 278.5714% | 85.7143% | 37.037% | 55% | 41.9355% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-29 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.04 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CDNA
2026-04-16 01:10:17
CareDx, Inc. has announced the divestiture of its Lab Products business to EuroBio Scientific for $170 million in cash. This strategic move aims to sharpen CareDx's focus on its core Precision Medicine Testing Services and Patient and Digital Solutions, which have shown strong revenue growth. The transaction is expected to simplify the company's operating model and enhance financial flexibility for future strategic investments.
2026-04-15 21:40:17
CareDx Inc (CDNA) experienced a 20% stock surge to $21 on April 15, 2026, following a positive Q1 pre-announcement and plans to divest its Lab Products segment. Despite a strong GF Score of 81 indicating growth potential, insider selling activities and ongoing profitability challenges present a mixed outlook for investors. The company, focused on healthcare solutions for transplant patients, particularly through testing services, has a market cap of $899.87 million, with its stock valued at a moderate price-to-sales ratio of 2.43.
2026-04-15 09:34:00
This article compares two small-cap medical companies, Omada Health and CareDx, to determine which offers a better investment opportunity. While both companies show strong revenue growth, Omada Health stands out due to its higher net dollar retention, more bullish analyst sentiment, and overall growth trajectory. CareDx, however, has a more profitable business model with higher net margins.
2026-04-15 07:39:34
CareDx, Inc. (Nasdaq: CDNA) will release its first quarter 2026 financial results after market close on Tuesday, April 28, 2026. The company will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day. Interested parties can access the webcast or register to participate in the live conference call via CareDx’s Investor Relations website.
2026-04-14 19:38:37
CareDx, Inc. (Nasdaq: CDNA) announced it will report its first quarter 2026 financial results after market close on Tuesday, April 28, 2026. The company will host a webcast and conference call on the same day at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties can access the live and archived webcast on the Investor Relations section of CareDx's website.
2026-04-12 23:43:16
The article focuses on the book value per share of CareDx, Inc. (DUS:1K9) on the Düsseldorf Stock Exchange. It provides a financial overview and indicates where users can find more detailed information and market data.
